{"id":"W2598954950","doi":"10.1158/2159-8290.cd-16-0795","title":"A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic <i>BRAF</i> -Mutant Colorectal Cancer","year":2017,"lang":"en","type":"article","venue":"Cancer Discovery","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":230,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Seventh Framework Programme; Deutschen Konsortium für Translationale Krebsforschung","keywords":"Cetuximab; Medicine; Colorectal cancer; Tolerability; Oncology; Internal medicine; Concomitant; Cancer; Population; Pharmacology; Adverse effect","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009313439,0.001124903,0.001630252,0.0004172871,0.0003883785,0.0007964521,0.0007678958,0.0009428512,0.001969518],"category_scores_gemma":[0.0004504828,0.0005564966,0.0008802552,0.0003575099,0.0007091158,0.0006672785,0.0002826529,0.003071203,0.0004724883],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000892434,"about_ca_system_score_gemma":0.001143115,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001110152,"about_ca_topic_score_gemma":0.002859778,"domain_scores_codex":[0.9996238,0.0001270839,0.00002481269,0.00007856903,0.00004867105,0.00009712089],"domain_scores_gemma":[0.9995759,0.00004155367,0.00008653932,0.00005551467,0.00003144033,0.00020903],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5010539,0.1343141,0.004329945,0.0006527545,0.00126677,0.0002223643,0.0003067222,0.003658797,0.2700046,0.0003887422,0.002209011,0.08159226],"study_design_scores_gemma":[0.25775,0.6955452,0.01004699,0.00002584518,0.0004884751,0.0003825408,0.00007487051,0.002016178,0.0308321,0.0001660737,0.0026274,0.00004439135],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9975241,0.0005020376,0.0003392129,0.0001170881,0.00005608466,0.0006545307,0.0002119969,0.00005041378,0.0005445179],"genre_scores_gemma":[0.9955314,0.0004872103,0.001162146,0.0001929054,0.00005235874,0.0007034534,0.0005991918,0.00001464982,0.001256832],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001969518,"threshold_uncertainty_score":0.006588697,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04112415896288415,"score_gpt":0.3710117573194283,"score_spread":0.3298875983565441,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}